Prostate Cancer

Clinically effective results in a group of patients with HRD-positive, chemotherapy-naïve metastatic castration resistant prostate cancer was induced with nivolumab plus rucaparib.

According to updated data from the phase 1b COSMIC-021 trial, treatment with cabozantinib and atezolizumab continued to demonstrate clinically meaningful activity in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, including those with high-risk clinical features.

Compared with a placebo, darolutamide demonstrated a similar safety profile in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) continuing androgen-deprivation therapy, with comparable adverse event onset and occurrence rates.

Darolutamide was statistically significantly associated with better episodic memory over enzaluamide, according to computerized cognitive assessment in men with metastatic castration-resistant prostate cancer.

Alan Lombard, PhD, shared insight on mechanisms of resistance to PARP inhibition with olaparib and explained how this resistance may be overcome.

According to new research, patients with a CDK12 mutation had a sensitivity to immune checkpoint inhibitors.

Based on 3 clinical trials, suggest that when managing toxicities in patients with non-metastatic castration-resistant prostate cancer, oncologists should look at the delta instead of the absolute numbers.

Phase 2 research highlights a wellness modality that may improve outcomes in men with prostate cancer.

An update from KEYNOTE-365 trial shows the promising efficacy of olaparib in combination with pembrolizumab for patients with post-docetaxel metastatic castration-resistant prostate cancer.

Regardless of prior antiandrogen therapy and its pretreatment duration, enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer.

Darolutamide has shown an impact on local symptoms in patients with nonmetastatic castration-resistant prostate cancer. One of the impacts was a delay in time to HRQOL deterioration.

Neal Shore, MD, FACS, discusses the use of metastases-free survival as the primary end point in the ARAMIS trial, which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).

Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.

Prospective clinical trial results of lutetium-PSMA suggest the therapy is safe for patients with locally advanced high-risk prostate cancer.

Neal Shore, MD, FACS, explains the relationship between the use of darolutamide and control of urinary and bowel adverse events, as observed in an analysis of the phase 3 ARAMIS clinical trial.

In the phase 3 HERO trial of relugolix versus standard of care leuprolide in men with advanced prostate cancer, relugolix failed to significantly delay onset of castration resistance.

Real-world evidence shows robust adherence rates and prostate-specific antigen response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

High adherence rates and favorable prostate-specific antigen response to apalutamide where seen in Patients with nonmetastatic castration-resistant prostate cancer.

Compared to those who are overweight or of a normal weight, patients who are obese are more likely to have better disease-specific and overall survival in metastatic castration-resistant prostate cancer.

In this companion article, Neeraj Agarwal, MD, discusses the role of genomic testing and imaging in the initial diagnosis, staging, and treatment of prostate cancer.

Alicia K. Morgans, MD, PhD, discusses the cardiovascular risks associated with androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer.

Smruthy Sivakumar, PhD, discusses a large-scale analysis of comprehensive genomic profiling utilization and ancestral characterization of the genomic landscape in patients with advanced prostate cancer.

P-PSMA-101, an autologous CAR-T product for the treatment of metastatic castrate-resistant prostate cancer, produces a durable response.

In this first video of the series, Neeraj Agarwal, MD, of the Huntsman Cancer Institute of the University of Utah explains the role of imaging and genomic testing in the diagnosis and treatment of prostate cancer.

In a 75-year-old patient with metastatic castration-resistant prostate cancer, a bone scan taken at 14-month follow-up showed evidence of 2 lesions in the right hip/pelvis, and abdominal/pelvic CT showed a 2.1-cm left pelvic lymphadenopathy.